BackgroundPatients with advanced KRAS-mutant non-small cell lung cancer (NSCLC) face a paucity of effective later-line therapies. While combining PD-1 inhibi Abstract Background: Patients with advanced KRAS-mutant non-small cell lung cancer (NSCLC) face a paucity of effective later-line therapies. While combining...
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC – IASLC RAS(ON) Inhibition: On the Path to Overcoming Therapeutic Resistance and Targeting More Variants in KRAS-Mutated NSCLC. Join this engaging CME symposium exploring the evolving treatment landscape of KRAS-mutated NSCLC....
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC - IASLC / Alex Spira, cancer, International Association for the Study of Lung Cancer, Kathryn Alex Spira and Kathryn C. Arbour 2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC –...
By: Julia Cipriano, MS, CMPP Posted: Tuesday, February 17, 2026 In a comparison of current efficacy and safety data for KRAS G12C inhibitors, sotorasib demonstrated greater cost-effectiveness than adagrasib for second- and subsequent-line treatment of KRAS G12C–mutated non–small cell lung...
In this interview, Mitchell von Itzstein, MD, discusses the challenges of treating KRAS-mutant non-small cell lung cancer (NSCLC), the potential of selinexor in combination with docetaxel, and the need for further research to refine treatment strategies for this patient population....
You are reading this latest preprint version Background Pulmonary sarcomatoid carcinoma (PSC) is a rare, highly aggressive non-small cell lung cancer (NSCLC) subtype (0.1%–4% of lung malignancies)[3]. Clinically, it mainly affects smokers, with half diagnosed at advanced stages; pathologically, it...
